BACKGROUND: Proton therapy (PT) improves outcomes in patients with nasal cavity (NC) and paranasal sinus (PNS) cancers. Herein, the authors have reported to their knowledge the largest series to date using intensity-modulated proton therapy (IMPT) in the treatment of these patients. METHODS: Between 2013 and 2018, a total of 86 consecutive patients (68 of whom were radiation-naive and 18 of whom were reirradiated) received PT to median doses of 70 grays and 67 grays relative biological effectiveness, respectively. Approximately 53% received IMPT. RESULTS: The median follow-up was 23.4 months (range, 1.7-69.3 months) for all patients and 28.1 months (range, 2.3-69.3 months) for surviving patients. The 2-year local control (LC), distant control, disease-free survival, and overall survival rates were 83%, 84%, 74%, and 81%, respectively, for radiation-naive patients and 77%, 80%, 54%, and 66%, respectively for reirradiated patients. Among radiation-naive patients, when compared with 3-dimensional conformal proton technique, IMPT significantly improved LC (91% vs 72%; P < .01) and independently predicted LC (hazard ratio, 0.14; P = .01). Sixteen radiation-naive patients (24%) experienced acute grade 3 toxicities; 4 (6%) experienced late grade 3 toxicities (osteoradionecrosis, vision loss, soft-tissue necrosis, and soft tissue fibrosis) (grading was performed according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 5.0]). Slightly inferior LC was noted for patients undergoing reirradiation with higher complications: 11% experienced late grade 3 toxicities (facial pain and brain necrosis). Patients treated with reirradiation had more grade 1 to 2 radionecrosis than radiation-naive patients (brain: 33% vs 7% and osteoradionecrosis: 17% vs 3%). CONCLUSIONS: PT achieved remarkable LC for patients with nasal cavity and paranasal sinus cancers with lower grade 3 toxicities relative to historical reports. IMPT has the potential to improve the therapeutic ratio in these malignancies and is worthy of further investigation.
BACKGROUND: Proton therapy (PT) improves outcomes in patients with nasal cavity (NC) and paranasal sinus (PNS) cancers. Herein, the authors have reported to their knowledge the largest series to date using intensity-modulated proton therapy (IMPT) in the treatment of these patients. METHODS: Between 2013 and 2018, a total of 86 consecutive patients (68 of whom were radiation-naive and 18 of whom were reirradiated) received PT to median doses of 70 grays and 67 grays relative biological effectiveness, respectively. Approximately 53% received IMPT. RESULTS: The median follow-up was 23.4 months (range, 1.7-69.3 months) for all patients and 28.1 months (range, 2.3-69.3 months) for surviving patients. The 2-year local control (LC), distant control, disease-free survival, and overall survival rates were 83%, 84%, 74%, and 81%, respectively, for radiation-naive patients and 77%, 80%, 54%, and 66%, respectively for reirradiated patients. Among radiation-naive patients, when compared with 3-dimensional conformal proton technique, IMPT significantly improved LC (91% vs 72%; P < .01) and independently predicted LC (hazard ratio, 0.14; P = .01). Sixteen radiation-naive patients (24%) experienced acute grade 3 toxicities; 4 (6%) experienced late grade 3 toxicities (osteoradionecrosis, vision loss, soft-tissue necrosis, and soft tissue fibrosis) (grading was performed according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 5.0]). Slightly inferior LC was noted for patients undergoing reirradiation with higher complications: 11% experienced late grade 3 toxicities (facial pain and brain necrosis). Patients treated with reirradiation had more grade 1 to 2 radionecrosis than radiation-naive patients (brain: 33% vs 7% and osteoradionecrosis: 17% vs 3%). CONCLUSIONS: PT achieved remarkable LC for patients with nasal cavity and paranasal sinus cancers with lower grade 3 toxicities relative to historical reports. IMPT has the potential to improve the therapeutic ratio in these malignancies and is worthy of further investigation.
Authors: Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang Journal: J Clin Oncol Date: 2009-06-29 Impact factor: 44.544
Authors: John J Cuaron; Chang Chang; Michael Lovelock; Daniel S Higginson; Dennis Mah; Oren Cahlon; Simon Powell Journal: Int J Radiat Oncol Biol Phys Date: 2016-02-13 Impact factor: 7.038
Authors: Megan E Daly; Allen M Chen; M Kara Bucci; Ivan El-Sayed; Ping Xia; Michael J Kaplan; David W Eisele Journal: Int J Radiat Oncol Biol Phys Date: 2007-01-01 Impact factor: 7.038
Authors: Bradford S Hoppe; Lauren D Stegman; Michael J Zelefsky; Kenneth E Rosenzweig; Suzanne L Wolden; Snehal G Patel; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-08 Impact factor: 7.038
Authors: William M Mendenhall; Robert J Amdur; Christopher G Morris; Jessica Kirwan; Robert S Malyapa; Mikhail Vaysberg; John W Werning; Nancy P Mendenhall Journal: Laryngoscope Date: 2009-05 Impact factor: 3.325
Authors: Bradford S Hoppe; Suzanne L Wolden; Michael J Zelefsky; James G Mechalakos; Jatin P Shah; Dennis H Kraus; Nancy Lee Journal: Head Neck Date: 2008-07 Impact factor: 3.147
Authors: Bradford S Hoppe; Carl J Nelson; Daniel R Gomez; Lauren D Stegman; Abraham J Wu; Suzanne L Wolden; David G Pfister; Michael J Zelefsky; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-18 Impact factor: 7.038
Authors: Dauren Adilbay; Cristina Valero; Conall Fitzgerald; Avery Yuan; Ximena Mimica; Piyush Gupta; Richard J Wong; Jatin P Shah; Snehal G Patel; Ian Ganly; Marc A Cohen Journal: Head Neck Date: 2022-01-25 Impact factor: 3.147
Authors: J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti Journal: J Neurooncol Date: 2020-08-12 Impact factor: 4.130
Authors: Mauricio E Gamez; Samir H Patel; Lisa A McGee; Terence T Sio; Mark McDonald; Jack Phan; Daniel J Ma; Robert L Foote; Jean-Claude M Rwigema Journal: Int J Part Ther Date: 2021-06-25
Authors: Jung Julie Kang; Richard J Wong; Eric J Sherman; Alisa Rybkin; Sean M McBride; Nadeem Riaz; C Jillian Tsai; Yao Yu; Linda Chen; Kaveh Zakeri; Daphna Y Gelblum; Erin F Gillespie; Marc A Cohen; Jennifer R Cracchiolo; Ian Ganly; Snehal Patel; Bhuvanesh Singh; Jay O Boyle; Benjamin R Roman; Luc G Morris; Ashok R Shaha; Lara A Dunn; Alan L Ho; James V Fetten; Jatin P Shah; David G Pfister; Nancy Y Lee Journal: Cancer Date: 2020-07-08 Impact factor: 6.921
Authors: Xingzhe Li; Sarin Kitpanit; Anna Lee; Dennis Mah; Kevin Sine; Eric J Sherman; Lara A Dunn; Loren S Michel; James Fetten; Kaveh Zakeri; Yao Yu; Linda Chen; Jung Julie Kang; Daphna Y Gelblum; Sean M McBride; Chiaojung J Tsai; Nadeem Riaz; Nancy Y Lee Journal: JAMA Netw Open Date: 2021-06-01
Authors: Danmeng Huang; Steven J Frank; Vivek Verma; Nikhil G Thaker; Eric D Brooks; Matthew B Palmer; Ross F Harrison; Ashish A Deshmukh; Matthew S Ning Journal: Int J Part Ther Date: 2021-06-25
Authors: Roi Dagan; Haruka Uezono; Curtis Bryant; Adam L Holtzman; Christopher G Morris; William M Mendenhall Journal: Int J Part Ther Date: 2021-06-25